Use of a HIV derived accessory protein for the reactivation of latent HIV
AssigneeJanssen Sciences Ireland Unlimited Company
InventorDaniel Boden
Life of this patent
Estimating the term…
Abstract
The present invention concerns the use of a protein comprising at least a HIV-derived accessory protein tat (trans-activator of transcription) or any derivative thereof for the reactivation of latent human immunodeficiency virus (HIV) from cells present in a HIV-infected patient.
Claims11
1-9. (canceled)
A method of using a mutant protein of an HIV Tat to reverse HIV-1 latency, the mutant protein of an HIV Tat consisting of 57, 60, 64 or 66 amino acids and comprising the amino acid sequence of SEQ ID NO:
- 1.
A method of using a mutant protein of an HIV Tat to reverse HIV-1 latency, the mutant protein of an HIV Tat consisting of the amino acid sequence of SEQ ID NO:4.
A method of using a mutant protein of an HIV Tat to reverse HIV-1 latency, the mutant protein of an HIV Tat consisting of the amino acid sequence of SEQ ID NO:3.
Dependencies are inferred from the claim text.